Suppr超能文献

全板层深板层角膜移植与穿透性角膜移植治疗单纯疱疹病毒性角膜炎所致角膜白斑的长期比较。

Long-term comparison of full-bed deep lamellar keratoplasty with penetrating keratoplasty in treating corneal leucoma caused by herpes simplex keratitis.

机构信息

Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, People's Republic of China.

出版信息

Am J Ophthalmol. 2012 Feb;153(2):291-299.e2. doi: 10.1016/j.ajo.2011.07.020. Epub 2011 Oct 13.

Abstract

PURPOSE

To compare long-term outcomes of full-bed deep lamellar keratoplasty (DLK) with penetrating keratoplasty (PK) for treating corneal leucoma caused by herpes simplex keratitis (HSK).

DESIGN

Retrospective, comparative, interventional case series.

METHODS

setting: Institutional. patients: Inclusion criteria were patients with corneal scarring induced exclusively by HSK who underwent primary graft of full-bed DLK or PK and completed a minimum of 12 months postoperative follow-up. There was no significant difference of corneal scarring and vascularization between the 2 groups before surgery. Choosing PK or full-bed DLK depended on the patient's own willingness, except those patients with a preoperative endothelial cell count of less than 700 cells/mm(2) or whose endothelial cell count was undetectable were encouraged to undergo only PK. Exclusion criteria were patients with a past history of corneal perforation, nonprimary graft, non-HSK-related corneal scars, and failure to complete a minimum of 12 months of postoperative follow-up. Fifty-eight eyes of 58 patients in the full-bed DLK group and 63 eyes of 63 patients in the PK group met the inclusion criteria. main outcome measures: Postoperative managements, recurrence of HSK, graft rejection, graft survival rate, visual acuity, and corneal endothelial density.

RESULTS

The mean postoperative follow-up duration was 45.8 ± 30.9 months in the full-bed DLK group and 47.9 ± 27.2 months in the PK group (P = .70). As compared with the PK group, the full-bed DLK group experienced earlier suture removal (P = .01), needed fewer postoperative visits (P < .001), and had a higher proportion of eyes with full withdrawal of oral acyclovir (P < .001) and topical corticosteroid (P < .001). There were a total of 21 episodes of recurrent HSK in the PK group, more frequent than the 7 episodes in the full-bed DLK group, among which recurrent epithelial keratitis amounted to 13 episodes in the PK group, remarkably more frequent than the 1 episode in the full-bed DLK group. Twenty-six eyes (41.3%) encountered rejection episodes in the PK group, but no rejection episode was found in the full-bed DLK group (P < .001). In 14 eyes in the PK group, graft failure developed because of graft rejection, recurrence of HSK, or both, whereas only in 1 eye in the full-bed DLK group did graft failure develop because of recurrence of HSK (P = .001). The clear graft survival rate in the full-bed DLK group was significantly higher than that in the PK group (P = .01). Corneal endothelial cell density was stable from 1 month through 5 years in the full-bed DLK group, but 51.3% cell loss was found in the PK group at 5 years after surgery. At the last visit, 66.1% of eyes with full-bed DLK grafts and 50.9% of eyes with PK grafts achieved a best-correct visual acuity of 0.5 or better (P = .10).

CONCLUSIONS

Advantages of full-bed DLK over PK are no allograft rejection, longer graft survival, earlier drug withdrawal of topical steroid and oral acyclovir, less recurrence of HSK, and fewer follow-up visits. Full-bed DLK is preferable for treating HSK-induced corneal scarring with relatively healthy endothelium and with no history of perforation.

摘要

目的

比较全层深板层角膜移植术(DLK)与穿透性角膜移植术(PK)治疗单纯疱疹性角膜炎(HSK)所致角膜白斑的长期疗效。

设计

回顾性、对比性、干预性病例系列研究。

方法

地点:机构。患者:纳入标准为仅由 HSK 引起角膜瘢痕,行初次全层 DLK 或 PK 移植,并完成至少 12 个月术后随访的患者。两组患者术前角膜瘢痕和血管化无显著差异。选择 PK 或全层 DLK 取决于患者自身意愿,但术前内皮细胞计数小于 700 个/mm²或内皮细胞计数无法检测的患者,仅鼓励行 PK。排除标准为有既往角膜穿孔史、非初次移植、非 HSK 相关角膜瘢痕、未完成至少 12 个月术后随访的患者。全层 DLK 组 58 只眼和 PK 组 63 只眼符合纳入标准。

主要观察指标

术后处理、HSK 复发、移植排斥、移植物存活率、视力和角膜内皮密度。

结果

全层 DLK 组的平均术后随访时间为 45.8 ± 30.9 个月,PK 组为 47.9 ± 27.2 个月(P =.70)。与 PK 组相比,全层 DLK 组更早去除缝线(P =.01),需要更少的术后就诊次数(P <.001),并且有更高比例的患者完全停用口服阿昔洛韦(P <.001)和局部皮质类固醇(P <.001)。PK 组共有 21 例 HSK 复发,比全层 DLK 组的 7 例更频繁,其中 PK 组复发性上皮性角膜炎有 13 例,明显多于全层 DLK 组的 1 例。PK 组有 26 只眼(41.3%)发生排斥反应,而全层 DLK 组未发生排斥反应(P <.001)。PK 组有 14 只眼因排斥反应、HSK 复发或两者同时导致移植物失功,而全层 DLK 组仅有 1 只眼因 HSK 复发导致移植物失功(P =.001)。全层 DLK 组的透明移植物存活率明显高于 PK 组(P =.01)。全层 DLK 组角膜内皮细胞密度在 1 个月至 5 年内保持稳定,但 PK 组在术后 5 年内发现 51.3%的细胞丢失。末次随访时,全层 DLK 组 66.1%的移植物和 PK 组 50.9%的移植物获得了最佳矫正视力 0.5 或以上(P =.10)。

结论

全层 DLK 优于 PK 的优势在于无同种异体排斥反应、移植物存活率更长、更早停用局部皮质类固醇和口服阿昔洛韦、HSK 复发更少、随访次数更少。全层 DLK 适用于治疗单纯疱疹性角膜炎所致角膜瘢痕,且内皮相对健康、无穿孔史的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验